{
    "clinical_study": {
        "@rank": "149522", 
        "acronym": "DP4", 
        "arm_group": [
            {
                "arm_group_label": "Diclofenac sodium 5 mg/mL", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Diclofenac sodium 12.5 mg/mL", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Diclofenac sodium 25 mg/mL", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Diclofenac sodium 50 mg/mL", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo 1 mL", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomised, double-blind, placebo-controlled, parallel group study in\n      approximately 75 patients undergoing surgical removal of an impacted lower third molar."
        }, 
        "brief_title": "Injectable Diclofenac for the Prevention of Post-operative Dental Pain", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Out-patients of either gender.\n\n          2. Patients aged \u2265 18 to \u2264 65 years old.\n\n          3. Subjects able and willing to give their written consent prior to inclusion in the\n             study.\n\n          4. Female subjects of childbearing potential must (1) have a negative urine pregnancy\n             test at the inclusion visit, (2) be using an appropriate method of contraception\n             according to the definition of Note of ICH M3 Guideline (implants, injectables,\n             combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner),\n             and (3) be willing to continue using the contraceptive method throughout the entire\n             study period.\n\n          5. Subjects must (1) be able to comprehend the full nature and purpose of the study,\n             including possible risks and side effects, (2) fully co-operate with the\n             Investigator, (3) comply with the requirements of the entire study.\n\n          6. Patients undergoing surgical extraction of a single, fully or partially impacted\n             mandibular 3rd molar requiring bone removal.\n\n        Exclusion Criteria:\n\n        General\n\n          1. Patients refusing to give written informed consent.\n\n          2. Patients not able to understand the purposes of the study or not willing to return\n             for the control visits.\n\n          3. Patients with major psychiatric disorders that, in the investigator's opinion, could\n             compromise study participation.\n\n          4. Patients enrolled in any clinical trial in the previous 3 months.\n\n          5. Employees of the study centre with direct involvement in the proposed study or other\n             studies under the direction of the main investigator or study centre, as well as\n             family members of the employees or investigator.\n\n          6. Pregnant or breast-feeding women.\n\n          7. Alcohol or drug abuse in the previous 12 months.\n\n          8. Clinically significant or unstable concomitant disease whose sequelae might interfere\n             with the study evaluation parameters."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706588", 
            "org_study_id": "12UK/DCsc04"
        }, 
        "intervention": {
            "arm_group_label": [
                "Diclofenac sodium 5 mg/mL", 
                "Diclofenac sodium 12.5 mg/mL", 
                "Diclofenac sodium 25 mg/mL", 
                "Diclofenac sodium 50 mg/mL", 
                "Placebo 1 mL"
            ], 
            "description": "One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.", 
            "intervention_name": "Diclofenac sodium", 
            "intervention_type": "Drug", 
            "other_name": "Diclofenac HPBCD"
        }, 
        "intervention_browse": {
            "mesh_term": "Diclofenac"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "diclofenac, postsurgical pain, oral surgery", 
        "lastchanged_date": "July 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United Kingdom", 
                    "zip": "B4 6NN"
                }, 
                "name": "The School of Dentistry University of Birmingham"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "5", 
        "official_title": "Preliminary Evaluation of the Efficacy and Local Tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, Administered Locally Prior to Surgery for the Prevention of Post-operative Pain After Third Molar Surgery", 
        "overall_official": {
            "affiliation": "The School of Dentistry, University of Birmingham", 
            "last_name": "Thomas Dietrich, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pain will be scored by the patient at the end of surgery (time 0) and at 15-minute intervals after surgery for a total of 6 hours on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).", 
            "measure": "Area Under the Curve (AUC) of the pain scores.", 
            "safety_issue": "No", 
            "time_frame": "Pain scores will be measured over the time from end of surgery (time 0) to the 6 hour post-surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706588"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pain Intensity", 
                "safety_issue": "No", 
                "time_frame": "Pain will be scored every 15 minutes up to to 6 hours postsurgery. Pain will be assessed at home hourly up to 12 hours post-surgery and twice daily every day up to 1 week after surgery."
            }, 
            {
                "measure": "Postsurgical extra-oral swelling", 
                "safety_issue": "No", 
                "time_frame": "measured at 6 hours postsurgery, at day 3 and 1 week postsurgery"
            }, 
            {
                "measure": "Trismus", 
                "safety_issue": "No", 
                "time_frame": "measured at 6 hours postsurgery, at day 3 and 1 week postsurgery"
            }, 
            {
                "measure": "Peak pain intensity", 
                "safety_issue": "No", 
                "time_frame": "measured from end of surgery up to 12 hours postsurgery"
            }, 
            {
                "measure": "Time to first use of rescue medication.", 
                "safety_issue": "No", 
                "time_frame": "measured from end of surgery up to 1 week postsurgery"
            }, 
            {
                "measure": "Amount of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "consumed by the patient every 15-minutes postsurgery up to 6 hours postsurgery"
            }, 
            {
                "measure": "Rescue medication consumption", 
                "safety_issue": "No", 
                "time_frame": "consumed by the patient from end of surgery up to 24 and up to 48 hours postsurgery"
            }, 
            {
                "measure": "Patient and investigator global evaluation of the effectiveness of treatment", 
                "safety_issue": "No", 
                "time_frame": "at 6 hour postsurgery and on Day 3"
            }, 
            {
                "measure": "time to onset of pain", 
                "safety_issue": "No", 
                "time_frame": "measured from end of surgery up to 12 hours postsurgery"
            }, 
            {
                "measure": "wound healing", 
                "safety_issue": "Yes", 
                "time_frame": "at 6 hour postsurgery, and on day 3 and 1 week postsurgery"
            }, 
            {
                "measure": "recurrent bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "every hour up to 6 hour postsurgery"
            }, 
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "presurgery (within 30 days from surgery), at day of surgery (day 1), day 3 and 1 week postsurgery."
            }, 
            {
                "measure": "Number of patients with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "from signature of the informed consent to 1 week postsurgery"
            }
        ], 
        "source": "IBSA Institut Biochimique SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IBSA Institut Biochimique SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}